-
1
-
-
33845340507
-
Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis
-
DOI 10.2337/dc06-1120
-
Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering effcacy: a meta-regression analysis. Diabetes Care. 2006;29:2137-2139. (Pubitemid 44871202)
-
(2006)
Diabetes Care
, vol.29
, Issue.9
, pp. 2137-2139
-
-
Bloomgarden, Z.T.1
Dodis, R.2
Viscoli, C.M.3
Holmboe, E.S.4
Inzucchi, S.E.5
-
2
-
-
77949416255
-
Relationship of baseline HbA1c and effcacy of current glucose-lowering therapies: A meta-analysis of randomized clinical trials
-
DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and effcacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309-317.
-
(2010)
Diabet Med.
, vol.27
, pp. 309-317
-
-
Defronzo, R.A.1
Stonehouse, A.H.2
Han, J.3
Wintle, M.E.4
-
3
-
-
77958172772
-
The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis
-
Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859-1864.
-
(2010)
Diabetes Care.
, vol.33
, pp. 1859-1864
-
-
Sherifali, D.1
Nerenberg, K.2
Pullenayegum, E.3
Cheng, J.E.4
Gerstein, H.C.5
-
4
-
-
73349102524
-
The safety and effcacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: An overview of the LEAD 1-5 studies
-
Blonde L, Russell-Jones D. The safety and effcacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11(suppl 3):26-34.
-
(2009)
Diabetes Obes Metab.
, vol.11
, Issue.SUPPL. 3
, pp. 26-34
-
-
Blonde, L.1
Russell-Jones, D.2
-
5
-
-
67649666737
-
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
-
(LEAD-6 Study Group).
-
Buse JB, Rosenstock J, Sesti G, et al (LEAD-6 Study Group). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
-
(2009)
Lancet.
, vol.374
, pp. 39-47
-
-
Buse, J.B.1
Rosenstock, J.2
Sesti, G.3
-
6
-
-
77952309372
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial
-
1860 -LIRA-DPP-4 Study Group)
-
Pratley RE, Nauck M, Bailey T, et al (1860-LIRA-DPP-4 Study Group). Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456.
-
(2010)
Lancet.
, vol.375
, pp. 1447-1456
-
-
Pratley, R.E.1
Nauck, M.2
Bailey, T.3
-
7
-
-
26944477362
-
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
-
(GWAA Study Group).
-
Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (GWAA Study Group). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143:559-569.
-
(2005)
Ann Intern Med.
, vol.143
, pp. 559-569
-
-
Heine, R.J.1
Van Gaal, L.F.2
Johns, D.3
Mihm, M.J.4
Widel, M.H.5
Brodows, R.G.6
-
8
-
-
34247259577
-
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial
-
Zinman B, Hoogwerf BJ, Durán Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial [published correction appears in Ann Intern Med. 2007;146:896]. Ann Intern Med. 2007;146:477-485 (Pubitemid 351650556)
-
(2007)
Annals of Internal Medicine
, vol.146
, Issue.7
, pp. 477-485
-
-
Zinman, B.1
Hoogwerf, B.J.2
Duran Garcia, S.3
Milton, D.R.4
Giaconia, J.M.5
Kim, D.D.6
Trautmann, M.E.7
Brodows, R.G.8
-
9
-
-
77953951577
-
American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes
-
American Association of Clinical Endocrinologists Board of Directors and American College of Endocrinologists Board of Trustees
-
American Association of Clinical Endocrinologists Board of Directors and American College of Endocrinologists Board of Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16:155-156.
-
(2010)
Endocr Pract.
, vol.16
, pp. 155-156
-
-
-
10
-
-
59449101432
-
Liraglutide versus glimepiride monother-apy for type 2 diabetes (LEAD-3 Mono): A randomised 52-week phase III double-blind parallel-treatment trial
-
(LEAD-3 [Mono] Study Group)
-
Garber A, Henry R, Ratner R, et al (LEAD-3 [Mono] Study Group). Liraglutide versus glimepiride monother-apy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
-
(2009)
Lancet.
, vol.373
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
-
11
-
-
62449129181
-
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
-
(LEAD-1 SU Study Group).
-
Marre M, Shaw J, Brändle M, et al (LEAD-1 SU Study Group). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278.
-
(2009)
Diabet Med
, vol.26
, pp. 268-278
-
-
Marre, M.1
Shaw, J.2
Brändle, M.3
-
12
-
-
62449169287
-
Effcacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metfor-min, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
-
(LEAD-2 Study Group).
-
Nauck M, Frid A, Hermansen K, et al (LEAD-2 Study Group). Effcacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metfor-min, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84-90.
-
(2009)
Diabetes Care.
, vol.32
, pp. 84-90
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
-
13
-
-
69949117621
-
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): A randomised controlled trial
-
(Liraglutide Effect and Action in Diabetes 5 [LEAD-5] Met+SU Study Group)
-
Russell-Jones D, Vaag A, Schmitz O, et al (Liraglutide Effect and Action in Diabetes 5 [LEAD-5] Met+SU Study Group). Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.
-
(2009)
Diabetologia.
, vol.52
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
-
14
-
-
67650066860
-
Effcacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met-formin and thiazolidinedione in patients with type 2 dia-betes (LEAD-4 Met+TZD) [published correction appears in Diabetes Care. 2010; 33:692]
-
(LEAD-4 Study Investigators).
-
Zinman B, Gerich J, Buse JB, et al (LEAD-4 Study Investigators). Effcacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met-formin and thiazolidinedione in patients with type 2 dia-betes (LEAD-4 Met+TZD) [published correction appears in Diabetes Care. 2010;33:692]. Diabetes Care. 2009;32: 1224-1230.
-
(2009)
Diabetes Care.
, vol.32
, pp. 1224-1230
-
-
Zinman, B.1
Gerich, J.2
Buse, J.B.3
-
15
-
-
0037569239
-
Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?
-
DOI 10.1185/030079903125001695
-
Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the metabolic effects of rosiglitazone infuenced by baseline glycaemic control? Curr Med Res Opin. 2003;19:192-199 (Pubitemid 36613002)
-
(2003)
Current Medical Research and Opinion
, vol.19
, Issue.3
, pp. 192-199
-
-
Goldstein, B.J.1
Cobitz, A.R.2
Hand, L.M.3
Chen, H.4
-
16
-
-
33751335302
-
1c: A meta-analysis of published randomized clinical trials
-
DOI 10.1185/030079906X148328
-
Phatak HM, Yin DD. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials. Curr Med Res Opin. 2006;22:2267-2278. (Pubitemid 44801495)
-
(2006)
Current Medical Research and Opinion
, vol.22
, Issue.11
, pp. 2267-2278
-
-
Phatak, H.M.1
Yin, D.D.2
-
17
-
-
33746433601
-
Effects of quality improvement strategies for type 2 diabetes on glycemic control: A meta-regression analysis
-
DOI 10.1001/jama.296.4.427
-
Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA. 2006; 296:427-440. (Pubitemid 44127527)
-
(2006)
Journal of the American Medical Association
, vol.296
, Issue.4
, pp. 427-440
-
-
Shojania, K.G.1
Ranji, S.R.2
McDonald, K.M.3
Grimshaw, J.M.4
Sundaram, V.5
Rushakoff, R.J.6
Owens, D.K.7
-
18
-
-
85038456735
-
-
Accessed for verifcation November 7
-
American Association of Clinical Endocrinologists. AACE/ACE diabetes algorithm for glycemic control. https://aace.com/sites/default/files/ GlycemicControl AlgorithmPPT.pdf. Accessed for verifcation November 7, 2011.
-
(2011)
AACE/ACE Diabetes Algorithm for Glycemic Control.
-
-
-
19
-
-
19944368427
-
Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine
-
DOI 10.2337/diacare.28.6.1282
-
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R (AT.LANTUS Study Group). Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282-1288. (Pubitemid 40756686)
-
(2005)
Diabetes Care
, vol.28
, Issue.6
, pp. 1282-1288
-
-
Davies, M.1
Storms, F.2
Shutler, S.3
Bianchi-Biscay, M.4
Gomis, R.5
|